Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer

Laura Maria Krabbe, Mary E. Westerman, Vitaly Margulis, Ganesh Raj, Arthur I Sagalowsky, Kevin D Courtney, Yull E Arriaga, Yair Lotan

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Introduction: To reassess use of perioperative chemotherapy in muscle-invasive bladder cancer (MIBC) following implementation of monthly multidisciplinary meetings to facilitate optimal oncologic treatment. We previously reported from 2003 to 2008 17% of eligible patients with bladder cancer received cisplatin-based neoadjuvant chemotherapy (NAC) at our institution. Materials and methods: A retrospective review of all patients who underwent radical cystectomy (RC) between 2008 and 2012 was performed. Information on clinical and pathologic stage, renal function, perioperative chemotherapy (CTX) use and oncologic outcomes was collected. Rationale for utilization decisions was obtained from physician encounter notes. Primary outcome was use of CTX among eligible patients. Secondary measures were type of CTX, pathologic and survival outcomes. Results: Among 261 patients undergoing RC for bladder cancer, 162 were eligible for NAC. Overall 40.7% (n = 66) received NAC, and 86.4% were given platinum. Patients given NAC were younger and had more advanced clinical stage. The degree of chronic kidney disease (CKD) (0-3) did not impact likelihood of receiving NAC. NAC patients were more likely to be downstaged to non-muscle-invasive disease (21.2% versus 7.3% p < 0.01) or have a complete pathologic response (12.1% versus 3.1% p = 0.025). Receipt of NAC did not affect oncologic outcomes. Following RC 22.3% of high risk patients (n = 112) received adjuvant chemotherapy (AC). Conclusions: Our use of cisplatin-based NAC improved from 17% to 35% and overall utilization of NAC increased from 22% to 41%. NAC led to improved pT0 rates and increased pathologic downstaging. The degree of CKD (0-3) did not impact likelihood of receiving NAC. AC use decreased in part due to higher utilization of NAC.

Original languageEnglish (US)
Pages (from-to)7865-7875
Number of pages11
JournalCanadian Journal of Urology
Volume22
Issue number4
StatePublished - 2015

Fingerprint

Urinary Bladder Neoplasms
Drug Therapy
Muscles
Cystectomy
Adjuvant Chemotherapy
Chronic Renal Insufficiency
Cisplatin
Platinum

Keywords

  • Bladder cancer
  • Chemotherapy
  • Cisplatin
  • Radical cystectomy
  • Utilization

ASJC Scopus subject areas

  • Urology

Cite this

Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer. / Krabbe, Laura Maria; Westerman, Mary E.; Margulis, Vitaly; Raj, Ganesh; Sagalowsky, Arthur I; Courtney, Kevin D; Arriaga, Yull E; Lotan, Yair.

In: Canadian Journal of Urology, Vol. 22, No. 4, 2015, p. 7865-7875.

Research output: Contribution to journalArticle

@article{4363cae8b14946288dac8d4a6c556295,
title = "Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer",
abstract = "Introduction: To reassess use of perioperative chemotherapy in muscle-invasive bladder cancer (MIBC) following implementation of monthly multidisciplinary meetings to facilitate optimal oncologic treatment. We previously reported from 2003 to 2008 17{\%} of eligible patients with bladder cancer received cisplatin-based neoadjuvant chemotherapy (NAC) at our institution. Materials and methods: A retrospective review of all patients who underwent radical cystectomy (RC) between 2008 and 2012 was performed. Information on clinical and pathologic stage, renal function, perioperative chemotherapy (CTX) use and oncologic outcomes was collected. Rationale for utilization decisions was obtained from physician encounter notes. Primary outcome was use of CTX among eligible patients. Secondary measures were type of CTX, pathologic and survival outcomes. Results: Among 261 patients undergoing RC for bladder cancer, 162 were eligible for NAC. Overall 40.7{\%} (n = 66) received NAC, and 86.4{\%} were given platinum. Patients given NAC were younger and had more advanced clinical stage. The degree of chronic kidney disease (CKD) (0-3) did not impact likelihood of receiving NAC. NAC patients were more likely to be downstaged to non-muscle-invasive disease (21.2{\%} versus 7.3{\%} p < 0.01) or have a complete pathologic response (12.1{\%} versus 3.1{\%} p = 0.025). Receipt of NAC did not affect oncologic outcomes. Following RC 22.3{\%} of high risk patients (n = 112) received adjuvant chemotherapy (AC). Conclusions: Our use of cisplatin-based NAC improved from 17{\%} to 35{\%} and overall utilization of NAC increased from 22{\%} to 41{\%}. NAC led to improved pT0 rates and increased pathologic downstaging. The degree of CKD (0-3) did not impact likelihood of receiving NAC. AC use decreased in part due to higher utilization of NAC.",
keywords = "Bladder cancer, Chemotherapy, Cisplatin, Radical cystectomy, Utilization",
author = "Krabbe, {Laura Maria} and Westerman, {Mary E.} and Vitaly Margulis and Ganesh Raj and Sagalowsky, {Arthur I} and Courtney, {Kevin D} and Arriaga, {Yull E} and Yair Lotan",
year = "2015",
language = "English (US)",
volume = "22",
pages = "7865--7875",
journal = "The Canadian journal of urology",
issn = "1195-9479",
publisher = "Canadian Journal of Urology",
number = "4",

}

TY - JOUR

T1 - Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer

AU - Krabbe, Laura Maria

AU - Westerman, Mary E.

AU - Margulis, Vitaly

AU - Raj, Ganesh

AU - Sagalowsky, Arthur I

AU - Courtney, Kevin D

AU - Arriaga, Yull E

AU - Lotan, Yair

PY - 2015

Y1 - 2015

N2 - Introduction: To reassess use of perioperative chemotherapy in muscle-invasive bladder cancer (MIBC) following implementation of monthly multidisciplinary meetings to facilitate optimal oncologic treatment. We previously reported from 2003 to 2008 17% of eligible patients with bladder cancer received cisplatin-based neoadjuvant chemotherapy (NAC) at our institution. Materials and methods: A retrospective review of all patients who underwent radical cystectomy (RC) between 2008 and 2012 was performed. Information on clinical and pathologic stage, renal function, perioperative chemotherapy (CTX) use and oncologic outcomes was collected. Rationale for utilization decisions was obtained from physician encounter notes. Primary outcome was use of CTX among eligible patients. Secondary measures were type of CTX, pathologic and survival outcomes. Results: Among 261 patients undergoing RC for bladder cancer, 162 were eligible for NAC. Overall 40.7% (n = 66) received NAC, and 86.4% were given platinum. Patients given NAC were younger and had more advanced clinical stage. The degree of chronic kidney disease (CKD) (0-3) did not impact likelihood of receiving NAC. NAC patients were more likely to be downstaged to non-muscle-invasive disease (21.2% versus 7.3% p < 0.01) or have a complete pathologic response (12.1% versus 3.1% p = 0.025). Receipt of NAC did not affect oncologic outcomes. Following RC 22.3% of high risk patients (n = 112) received adjuvant chemotherapy (AC). Conclusions: Our use of cisplatin-based NAC improved from 17% to 35% and overall utilization of NAC increased from 22% to 41%. NAC led to improved pT0 rates and increased pathologic downstaging. The degree of CKD (0-3) did not impact likelihood of receiving NAC. AC use decreased in part due to higher utilization of NAC.

AB - Introduction: To reassess use of perioperative chemotherapy in muscle-invasive bladder cancer (MIBC) following implementation of monthly multidisciplinary meetings to facilitate optimal oncologic treatment. We previously reported from 2003 to 2008 17% of eligible patients with bladder cancer received cisplatin-based neoadjuvant chemotherapy (NAC) at our institution. Materials and methods: A retrospective review of all patients who underwent radical cystectomy (RC) between 2008 and 2012 was performed. Information on clinical and pathologic stage, renal function, perioperative chemotherapy (CTX) use and oncologic outcomes was collected. Rationale for utilization decisions was obtained from physician encounter notes. Primary outcome was use of CTX among eligible patients. Secondary measures were type of CTX, pathologic and survival outcomes. Results: Among 261 patients undergoing RC for bladder cancer, 162 were eligible for NAC. Overall 40.7% (n = 66) received NAC, and 86.4% were given platinum. Patients given NAC were younger and had more advanced clinical stage. The degree of chronic kidney disease (CKD) (0-3) did not impact likelihood of receiving NAC. NAC patients were more likely to be downstaged to non-muscle-invasive disease (21.2% versus 7.3% p < 0.01) or have a complete pathologic response (12.1% versus 3.1% p = 0.025). Receipt of NAC did not affect oncologic outcomes. Following RC 22.3% of high risk patients (n = 112) received adjuvant chemotherapy (AC). Conclusions: Our use of cisplatin-based NAC improved from 17% to 35% and overall utilization of NAC increased from 22% to 41%. NAC led to improved pT0 rates and increased pathologic downstaging. The degree of CKD (0-3) did not impact likelihood of receiving NAC. AC use decreased in part due to higher utilization of NAC.

KW - Bladder cancer

KW - Chemotherapy

KW - Cisplatin

KW - Radical cystectomy

KW - Utilization

UR - http://www.scopus.com/inward/record.url?scp=84939185760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939185760&partnerID=8YFLogxK

M3 - Article

C2 - 26267024

AN - SCOPUS:84939185760

VL - 22

SP - 7865

EP - 7875

JO - The Canadian journal of urology

JF - The Canadian journal of urology

SN - 1195-9479

IS - 4

ER -